Drug Type Small molecule drug |
Synonyms Fananserin (USAN/INN), RP 62203, RP-62203 |
Mechanism 5-HT2 receptor antagonists(Serotonin 2 (5-HT2) receptor antagonists), D4 receptor antagonists(Dopamine D4 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC23H24FN3O2S |
InChIKeyVGIGHGMPMUCLIQ-UHFFFAOYSA-N |
CAS Registry127625-29-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02656 | Fananserin | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anxiety Disorders | Phase 2 | US | - | - |
Anxiety Disorders | Phase 2 | FR | - | - |
Anxiety Disorders | Phase 2 | - | - | |
Depressive Disorder, Major | Phase 2 | US | - | - |
Depressive Disorder, Major | Phase 2 | FR | - | - |
Depressive Disorder, Major | Phase 2 | - | - | |
Schizophrenia | Phase 2 | US | - | - |
Schizophrenia | Phase 2 | FR | - | - |
Schizophrenia | Phase 2 | - | - |